Arbutus Biopharma (ABUS) 10-Q2019 Q1 Quarterly report

Filed: 6 May 19, 5:30pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Additionally, alleged, Antigenemia, apparent, arrangement, bank, bioavailable, biology, blood, body, borrowing, broadly, carcinoma, Circle, clarify, compelling, conference, confounding, conventional, counterparty, degradation, denominated, depression, disruption, EASL, element, elucidating, entry, essential, exemption, expired, expressly, felt, fight, foregoing, fulfill, goal, Gritsone, harbor, hepatocellular, higher, histological, historical, implicit, implied, inception, incidence, incremental, inflammation, injection, intention, intervention, Jacksonville, lack, largest, lifecycle, list, LLC, load, located, maintenance, master, Mode, monotherapy, morbidity, mortality, OnpattroTM, package, parallel, pathway, pausing, Pennsylvania, pharmacokinetic, prevalence, produced, reawaken, Reform, request, requested, reservoir, residual, respond, ROU, shortening, side, size, stake, stated, stimulator, stopped, substance, Supplemental, synthetic, tangible, toxicology, trajectory, underlying, unexplained, unknown, upcoming, vehicle, version, wrongfully

Removed: adjustment, Alexion, allocation, ALNY, amalgamated, announce, antisense, ATTR, August, bad, BC, bearing, binding, breach, cautioned, certificate, charge, charged, close, closeout, committee, communication, comparable, compete, competitive, component, continued, credit, criteria, customized, deferral, deferred, deposit, depreciation, discontinue, discounted, disposal, distinction, diversity, double, driven, earn, economic, effectively, embedded, ending, enrolled, entity, escalating, excluding, execute, executing, execution, exit, expansion, expiry, explicitly, exposure, Fargo, field, filing, final, finalized, finance, generate, grant, HCC, head, heading, hereof, immunotherapy, inclusive, Interbank, inventory, invested, involvement, IP, largely, law, LIBOR, loan, London, MAD, main, manufacturing, margin, Measurement, merger, met, minimum, MOA, neoantigen, netting, Offered, order, orphan, partner, pending, pgRNA, portfolio, practice, previously, principally, professional, Protiva, provision, purpose, qualified, quantum, rapidly, rare, reached, receivable, recognition, recognizing, reduced, release, render, repaid, replacement, repurchase, restricted, retention, review, reviewed, revise, SAD, secondary, secured, September, settlement, shipped, social, source, standalone, steering, successful, suggest, technical, temporary, terminate, terminated, terminating, tolerability, transthyretin, treated, TTR, unable, undetectable, unexpected, unrealized, validated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABUS transcripts

ABUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I David Hastings, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.	The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

Date: May 6, 2019



	/s/ David Hastings
	Name: David Hastings
	Title: Chief Financial Officer